Regen BioPharma Files Highly Dilutive $450K Regulation A Offering at Deep Discount Amid Going Concern Warning

summarizeSummary

Regen BioPharma Inc. filed a Regulation A offering to raise up to $450,000 at a significant discount to its current share price, indicating severe financial distress and substantial dilution for existing shareholders. The company also disclosed a going concern warning and recent highly dilutive share-based compensation to its CEO and a consultant.

check_boxKey Events

• Regulation A Offering Filed

  Regen BioPharma Inc. filed a Regulation A offering to raise up to $450,000 by issuing 100,000,000 shares of common stock at $0.0045 per share, a significant discount to the current market price of $0.009762.

• Substantial Share Dilution

  The offering, if fully subscribed, would increase the company's outstanding common shares by approximately 92.5% and represents over 42% of its current market capitalization.

• Going Concern Warning Issued

  Both management and the independent auditor have expressed substantial doubt about the company's ability to continue as a going concern, citing significant operating losses and a net working capital deficit of $6.2 million.

• Highly Dilutive Share-Based Compensation

  The company recently issued 40 million common shares (20 million each to the CEO and a consultant) as compensation, representing approximately 37% dilution to current shareholders, tied to a planned Phase I clinical trial.

auto_awesomeAnalysis

The filing highlights Regen BioPharma's critical financial state and its reliance on highly dilutive capital raises. The Regulation A offering aims to secure $450,000 by issuing up to 100 million shares at a deep discount of $0.0045 per share, which is approximately 54% below the current market price. This offering alone would nearly double the outstanding common shares and represents a substantial portion of the company's minimal market capitalization, signaling desperation for capital. The company explicitly states a "going concern" warning, reinforced by its independent auditor, due to significant operating losses and a substantial working capital deficit. Further exacerbating shareholder dilution, the company recently issued 40 million common shares to its CEO and a consultant as compensation for services related to a planned Phase I clinical trial. This issuance alone represents an additional 37% dilution to existing shareholders. The disclosure of the CEO's past disciplinary action by the NYSE for "excessive, unsuitable and discretionary trading" adds to the overall risk profile and raises governance concerns. Investors should be aware of the severe financial challenges, extreme dilution, and governance risks associated with this company.